Verve Therapeutics Inc VERV:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 5:51 PM EDT
6.65quote price arrow up+0.42 (+6.74%)
Volume
84,565
Close
6.23UNCH (UNCH)
Volume
1,144,905
52 week range
5.84 - 21.42
Loading...
  • Open6.47
  • Day High6.62
  • Day Low6.12
  • Prev Close6.23
  • 52 Week High21.42
  • 52 Week High Date06/16/23
  • 52 Week Low5.84
  • 52 Week Low Date05/01/24

Key Stats

  • Market Cap522.839M
  • Shares Out83.92M
  • 10 Day Average Volume1.41M
  • Dividend-
  • Dividend Yield-
  • Beta1.94
  • YTD % Change-55.31

KEY STATS

  • Open6.47
  • Day High6.62
  • Day Low6.12
  • Prev Close6.23
  • 52 Week High21.42
  • 52 Week High Date06/16/23
  • 52 Week Low5.84
  • 52 Week Low Date05/01/24
  • Market Cap522.839M
  • Shares Out83.92M
  • 10 Day Average Volume1.41M
  • Dividend-
  • Dividend Yield-
  • Beta1.94
  • YTD % Change-55.31

RATIOS/PROFITABILITY

  • EPS (TTM)-2.87
  • P/E (TTM)-2.17
  • Fwd P/E (NTM)-2.22
  • EBITDA (TTM)-215.749M
  • ROE (TTM)-36.03%
  • Revenue (TTM)16.049M
  • Gross Margin (TTM)-
  • Net Margin (TTM)-1,226.43%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/10/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Verve Therapeutics Inc

 

Profile

MORE
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic...
Burt Adelman M.D.
Independent Chairman of the Board
Sekar Kathiresan M.D.
Chief Executive Officer, Director
Andrew Ashe J.D.
President, Chief Operating Officer, General Counsel
Allison Dorval CPA
Chief Financial Officer
Address
201 Brookline Avenue, Suite 601
Boston, MA
02215
United States

Top Peers

SYMBOLLASTCHG%CHG
OABI
OmniAb Inc
4.54+0.04+0.89%
STTK
Shattuck Labs Inc
8.16-0.32-3.77%
OCS
Oculis Holding AG
12.02-0.14-1.15%
TSHA
Taysha Gene Therapies Inc
3.11+0.54+21.01%
KALV
Kalvista Pharmaceuticals Inc
12.01-0.48-3.84%